GeneDx Holdings Corp. (NASDAQ:WGS) Receives $101.63 Consensus Target Price from Analysts

Key Points

• GeneDx Holdings Corp. has received an average recommendation of "Moderate Buy" from eight research firms, with six analysts issuing buy ratings and two maintaining hold ratings.
• The average 1-year price target set by analysts for GeneDx is $101.63, with Guggenheim setting the highest target at $115.00.
• CFO Kevin Feeley and CEO Katherine Stueland recently sold significant shares of GeneDx, representing a decrease in their ownership positions; insiders sold a total of 561,641 shares valued at approximately $67.5 million in the last quarter.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $104.1250.

A number of analysts have issued reports on the company. Guggenheim reaffirmed a "buy" rating and issued a $115.00 target price (up previously from $88.00) on shares of GeneDx in a report on Monday, June 30th. Wall Street Zen raised GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Wells Fargo & Company raised their price objective on shares of GeneDx from $78.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Finally, Piper Sandler upped their target price on shares of GeneDx from $120.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday.

Insider Activity at GeneDx

In other GeneDx news, Director Jason Ryan sold 38,072 shares of the firm's stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $127.30, for a total value of $4,846,565.60. Following the completion of the sale, the director owned 103,284 shares in the company, valued at approximately $13,148,053.20. This trade represents a 26.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Katherine Stueland sold 9,657 shares of GeneDx stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $90.94, for a total value of $878,207.58. Following the sale, the chief executive officer directly owned 4,940 shares in the company, valued at $449,243.60. The trade was a 66.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 561,641 shares of company stock worth $67,551,904 over the last ninety days. Corporate insiders own 29.60% of the company's stock.

Institutional Investors Weigh In On GeneDx

A number of institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new position in shares of GeneDx in the 4th quarter worth approximately $35,000. GAMMA Investing LLC grew its position in GeneDx by 151.7% in the first quarter. GAMMA Investing LLC now owns 438 shares of the company's stock valued at $39,000 after acquiring an additional 264 shares during the period. Comerica Bank bought a new stake in GeneDx in the fourth quarter valued at $50,000. US Bancorp DE lifted its holdings in shares of GeneDx by 3,223.5% during the first quarter. US Bancorp DE now owns 565 shares of the company's stock valued at $50,000 after acquiring an additional 548 shares during the period. Finally, AlphaQuest LLC lifted its holdings in shares of GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company's stock valued at $70,000 after acquiring an additional 594 shares during the period. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Stock Performance

Shares of NASDAQ:WGS traded up $2.70 during trading on Friday, reaching $125.89. The stock had a trading volume of 447,115 shares, compared to its average volume of 609,383. The stock has a fifty day simple moving average of $106.99 and a two-hundred day simple moving average of $91.80. The company has a quick ratio of 2.70, a current ratio of 2.87 and a debt-to-equity ratio of 0.19. GeneDx has a 52 week low of $34.94 and a 52 week high of $136.00. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of 2,517.80 and a beta of 2.04.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.10 by $0.40. The business had revenue of $102.69 million for the quarter, compared to analyst estimates of $86.00 million. GeneDx had a net margin of 0.39% and a return on equity of 16.51%. GeneDx has set its FY 2025 guidance at EPS. As a group, analysts anticipate that GeneDx will post 0.97 earnings per share for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.